Kuros Biosciences (SIX:KURN) sold 1,151,606 new shares (excluding an over-allotment option of up to 200,000 shares) to existing and new investors at a price of CHF 12.50 per share. In total, Kuros raised gross proceeds of CHF 14.4 million (or CHF 16.9 million if the over-allotment option will be exercised in full). The new funds will fund Kuros’ commercial activities, in particular the preparation of the market launch of novel products MagnetOS as well as certain important activities for the ongoing Fibrin-PTH development programs. The capital increase was conducted as an “at market” rights offering and an offering for shares, for which rights were not exercised by way of a public offering in Switzerland and a private placement to qualified institutional investors outside of Switzerland Zürcher Kantonalbank, goetzpartners and Octavian were acting as Joint Placement Agents for Kuros in the offering.
VISCHER AG acted as Transaction Counsel und Listing Agent. The team is led by Dr. Matthias Staehelin (Partner) with Angelo Imperiale (Associate) and Dr. Peter Kühn (Managing Associate), all Corporate.